logo
  • About us
    • The Company in brief
    • Strategy
    • Market
    • Organisation
      • Management
      • Board of Directors
  • Our Drug Projects
    • Science
    • Pipeline
    • Our ongoing study
    • Disorders
      • Primary Biliary Cholangitis (PBC)
      • Hepatic Encephalopathy (HE)
      • Potential expansion
  • Our ongoing study
  • Investors
    • Financial Reports
    • Corporate Governance
    • General meetings
    • Calendar
    • Press Releases
  • Media
    • Press Releases
    • Presentations and posters
    • Subscribe
  • Contact

Presentations and posters

CEO Viktor Drvota presents at Redeye Theme Event Neurology 2025 – October 15

POSTER: CEO Viktor Drvota presents at Redeye Theme Event Neurology 2025 – October 15

EASL 2025: CGI-S Scale for PBC – Results of a focused training programme

EASL 2025: CGI-S Scale for PBC – Validation of a clinical trials outcome tool

  • Media
    • Press Releases
    • Presentations and posters
    • Subscribe

IR contact

Viktor Drvota
Viktor Drvota
CEO and Chairman of the Board
[email protected]

Press releases

  • November 19, 2025
    Umecrine Cognition publishes review highlighting the therapeutic potential of golexanolone in treating neuroinflammatory disorders
    STOCKHOLM – November 19, 2025. Umecrine Cognition today announced that a review article on golexanolone, a first-in-class drug candidate targeting...
  • November 17, 2025
    Umecrine Cognition reports early golexanolone treatment yields sustained benefit in a preclinical model of Parkinson’s disease
    STOCKHOLM – November 17, 2025. Umecrine Cognition AB today announced publication in Neuropharmacology of findings which show that early treatment...
  • October 9, 2025
    Notice to attend the Extraordinary General Meeting in Umecrine Cognition AB, at 2:30 p.m.
    STOCKHOLM – October 9, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary...
See all press releases

CONTACT

Viktor Drvota
CEO and Chairman of the Board
Phone +46 8-524 860 70
[email protected]

All contacts

VISITING ADDRESS

Umecrine Cognition AB
Karolinska Institutet Science Park
Nanna Svartz väg 6A,
171 65 Solna
Sweden

COMPANY INFORMATION

Umecrine Cognition AB
Registered office in Umeå
Reg no 556698-3655

  • Cookies
  • Privacy Policy